FDA Expands Approval Of GSK’s RSV Vaccine To Adults 50 To 59

Reuters (6/7, Roy, Santhosh, Singh) reported, “The U.S. Food and Drug Administration approved the expanded use of GSK’s respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age group.” GSK’s vaccine, Arexvy, “and vaccines from rivals Pfizer and Moderna are already approved for people aged 60 and older for the virus,” but “Arexvy has dominated the U.S. RSV vaccine market since its launch last year.” The CDC “is yet to sign off on the use of GSK’s vaccine in the expanded patient population. CDC’s panel of independent experts will convene between June 26 to 28.”